What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

President Donald Trump has received updated flu and COVID-19 booster shots in preparation for upcoming travel, the president’s physician announced Oct. 10. Sean P. Barbabella, a U.S. Navy captain, ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Shares of Moderna (MRNA) are up $1.97, or 8% to $26.67 in morning trading. Published first on TheFly – the ultimate source for real-time, ...

It’s no secret that our bodies’ ability to ward off pathogens and mount strong vaccine responses weakens with age, but ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

Eight breakthrough technologies that are redefining how we discover drugs, deliver care, and create a more connected and ...